Protedyne Appoints President, CEO and Chairman of the Board
News Feb 02, 2006
Protedyne Corporation has announced that Fran Tuttle has joined the company as President and Chief Executive Officer and will also join the company’s Board of Directors.
Protedyne also announced that Rolf Classon has been elected Chairman of the Board. Classon has served on Protedyne’s Board of Directors since August 2004.
Ms. Tuttle has over 25 years of experience in life sciences leadership. Most recently, she was Senior Vice President of Near Patient Testing at Bayer Diagnostics.
At Bayer, she was responsible for a worldwide business of $400 million. Before joining Bayer Diagnostics, she spent 20 years at Chiron Diagnostics (formerly Ciba Corning Diagnostics).
"We are very pleased to have Fran Tuttle join Protedyne," said Classon. "I have known and worked with Fran for a number of years and have great respect for her leadership ability and experience."
"Protedyne has established a strong foundation in laboratory automation and I see tremendous opportunities for growth, particularly in the diagnostics market."
"Having an industry veteran of Fran’s caliber join our team further validates Protedyne’s position as a leader in laboratory automation."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE